Septerna Inc. has officially commenced its Collaboration and License Agreement with Novo Nordisk A/S as of July 1, 2025. This follows the early termination of the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement, initially announced on May 13, 2025, marks a significant partnership between the two companies. Details of the agreement were previously summarized in a report filed with the Securities and Exchange Commission, with a full text expected to be included in Septerna's upcoming quarterly report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.